Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (61-70 of 234) with videos related to

Pageof 24
Sort By:
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2024
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysisDing-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 16, 2022
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
Future Oncology (London, England)|April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
European Urology|October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapyPeter F A Mulders, Arturo Molina, Michael Marberger, et al.
British Journal of Haematology|September 21, 2006
High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer, Peter M Venner, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2018
Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer PatientsJuozas Gordevičius, Algimantas Kriščiūnas, Daniel E Groot, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Frontiers in Oncology|September 30, 2022
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockadeJean-Michel Lavoie, Priya Baichoo, Elizabeth Chavez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Pageof 24

Showing results (61-70 of 234) with videos related to

Sort By:
Pageof 24
Urologic Oncology|May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancerEric Winquist, Malcolm J Moore, Kim N Chi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2024
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysisDing-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 16, 2022
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
Future Oncology (London, England)|April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
European Urology|October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapyPeter F A Mulders, Arturo Molina, Michael Marberger, et al.
British Journal of Haematology|September 21, 2006
High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer, Peter M Venner, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2018
Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer PatientsJuozas Gordevičius, Algimantas Kriščiūnas, Daniel E Groot, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Frontiers in Oncology|September 30, 2022
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockadeJean-Michel Lavoie, Priya Baichoo, Elizabeth Chavez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Pageof 24